SSRI单药治疗对减重手术后体重结局的影响
本研究回顾性纳入2020年7月至2023年6月接受袖状胃切除或Roux-en-Y胃旁路的成人,比较术前使用SSRI单药并持续术后至少12个月的焦虑/抑郁患者与无焦虑/抑郁患者。倾向性评分匹配后,袖状胃切除组中SSRI患者3个月和12个月的EWL%及TWL%显著更低,而胃旁路组各时间点无显著差异。
要点
- 袖状胃切除后持续SSRI单药治疗与3个月和12个月体重减轻更差相关。
- 胃旁路术后SSRI单药治疗未显示对体重减轻的不良影响。
- 术前咨询和术式选择可考虑患者SSRI使用情况。
核心结论
- 持续SSRI单药治疗可能与袖状胃切除术后短期和中期体重减轻较差相关,但似乎不影响胃旁路术后的体重减轻。
研究设计与样本
- 回顾性队列研究,纳入2020年7月至2023年6月接受袖状胃切除或Roux-en-Y胃旁路的成人,共799例,其中731例无焦虑/抑郁,68例焦虑/抑郁接受SSRI单药治疗。
- 采用人口学和临床变量进行1:1倾向性评分匹配。
主要发现
- 未调整分析中,两种术式队列的TWL%或EWL%组间均无显著差异。
- 倾向性评分匹配后,袖状胃切除组中SSRI患者3个月EWL%为32.5% vs. 42.8%(p=0.035),12个月为47.3% vs. 63.5%(p<0.001)。
- 袖状胃切除组中SSRI患者3个月TWL%为15.1% vs. 20.0%(p=0.015),12个月为22.4% vs. 28.5%(p=0.034)。
- 胃旁路组各时间点TWL%或EWL%均无显著差异(p>0.274)。
临床怎么用
- 这些发现可能有助于术前咨询、术式选择和接受SSRI治疗的减重患者的术后管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for anxiety and depression among patients undergoing metabolic and bariatric surgery (MBS). SSRIs are associated with weight gain in the general population, and therefore may potentially hinder weight loss post-bariatric surgery. This study evaluated the effect of continued SSRI monotherapy on weight loss outcomes following sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). METHODS: A retrospective cohort study of adults who underwent SG or RYGB between July 2020 and June 2023 was conducted. Patients with depression or anxiety receiving SSRI monotherapy before surgery and continuing treatment for at least 12 months postoperatively were compared with patients without depression or anxiety by surgical procedure. Propensity-score matching was performed in a 1:1 ratio using demographic and clinical variables. Primary outcomes were total weight loss percentage (TWL%) and excess weight loss percentage (EWL%) at 3, 6, and 12 months. RESULTS: Among 799 patients, 731 were included in the no anxiety/depression (No A/D) group and 68 in the anxiety/depression with SSRI monotherapy (A/D SSRI) group. Unadjusted analyses demonstrated no significant differences in TWL% or EWL% between groups in either procedural cohort. Following propensity-score matching, patients undergoing SG in the A/D SSRI group achieved significantly lower EWL% at 3 months (32.5 vs. 42.8%, p = 0.035) and 12 months (47.3 vs. 63.5%, p < 0.001), as well as lower TWL% at 3 months (15.1 vs. 20.0%, p = 0.015) and 12 months (22.4 vs. 28.5%, p = 0.034). No significant differences in TWL% or EWL% were observed at any time point among patients undergoing RYGB (p > 0.274). CONCLUSIONS: Continued SSRI monotherapy may be associated with inferior short- and intermediate-term weight loss following sleeve gastrectomy, but does not appear to adversely affect weight loss after Roux-en-Y gastric bypass. These findings may inform preoperative counseling, procedure selection, and postoperative management of bariatric patients receiving SSRI therapy.
引用
- Cross-Najafi AA, Theisen EA, Samaniego JM, et al. SSRI monotherapy impacts weight loss outcomes following bariatric surgery. Surg Endosc. 2026. PMID: 42728436. doi:10.1007/s00464-026-13331-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。